Can Azithromycin Cause Rhabdomyolysis?
Yes, azithromycin can cause rhabdomyolysis, though this is a rare adverse effect that occurs primarily through two mechanisms: direct myotoxicity (especially in exercising or infected patients) and drug interactions with statins.
Direct Myotoxic Effect
Azithromycin has documented myotoxic potential as a standalone agent. A case report demonstrated that azithromycin triggered rhabdomyolysis with creatine kinase (CK) levels reaching 25,000 U/L after just two 500mg doses in a 17-year-old male who was exercising and had a febrile infection 1. The myalgias resolved within two days of discontinuation, and CK levels continuously declined with hydration and exercise avoidance.
The combination of azithromycin use with concurrent infection and physical exercise appears to create a particularly high-risk scenario for direct muscle toxicity 1.
Drug-Drug Interaction with Statins
The more clinically significant concern involves azithromycin's interaction with statins, particularly simvastatin. While azithromycin is generally considered safer than other macrolides (like clarithromycin or erythromycin) when co-prescribed with statins, it is not risk-free:
Pharmacovigilance data from FAERS identified azithromycin with a statistically significant reporting odds ratio of 2.94 (95% CI: 1.96-4.39) for rhabdomyolysis 2
WHO VigiBase analysis revealed 53 cases of rhabdomyolysis with concomitant azithromycin-statin use, with 23% occurring shortly after azithromycin initiation 3
The interaction appears strongest with CYP3A4-metabolized statins (simvastatin, atorvastatin, lovastatin) 3
Mechanism of Statin Interaction
Unlike clarithromycin or erythromycin, azithromycin only mildly inhibits CYP3A4. However, a "dual-hit" mechanism can occur:
- Azithromycin mildly inhibits simvastatin's hepatic CYP3A4 metabolism
- In patients with SLCO1B1 genetic polymorphisms (which reduce hepatic statin uptake), this combination significantly elevates serum statin concentrations 4
This interaction is particularly dangerous because azithromycin is often prescribed without consideration of statin co-administration, unlike other macrolides that carry explicit warnings 3.
Clinical Implications and Risk Stratification
High-Risk Scenarios:
- Patients on statins (especially simvastatin, atorvastatin, lovastatin) receiving azithromycin
- Exercising patients with concurrent infections
- Patients with SLCO1B1 polymorphisms (consider genetic testing if unexplained statin myopathy occurs) 4
- Immunocompromised patients with severe infections 5
Monitoring Approach:
- Warn patients on statins about muscle pain, weakness, or dark urine when prescribed azithromycin
- Consider temporary statin discontinuation during azithromycin course (typically 3-5 days)
- If rhabdomyolysis occurs, check CK levels (expect >10,000 IU/L for exertional, >5,000 IU/L for non-exertional) 6
- Assess acute kidney injury risk using McMahon score 6
Management:
- Immediately discontinue azithromycin and statins if rhabdomyolysis suspected
- Aggressive IV hydration (0.9% sodium chloride at 300 cc/hour) 7
- Avoid exercise until CK normalizes (typically 1-2 weeks) 6
- Monitor renal function closely
Important Caveats
The FDA drug label for azithromycin does not list rhabdomyolysis as a specific adverse effect 8, though it does warn about QT prolongation and other serious reactions. This represents a gap between post-marketing surveillance data and official labeling.
While rhabdomyolysis from azithromycin alone is rare, the combination with statins or in the context of exercise and infection creates meaningful risk that warrants clinical vigilance 1, 2, 3.